Search
01/01/2022
Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice
Reymundo A., Vilarrasa E., Baniandrés O., Rodríguez-Fernández-Freire L., Feltes R., Llamas-Velasco M., Daudén E.. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(10)DOI:10.1111/jdv.18317. PMID:35689497. IF:9.200(Q1/1D).
01/01/2022
Using Artificial Intelligence as a Diagnostic Decision Support Tool in Skin Disease: Protocol for an Observational Prospective Cohort Study
Escalé-Besa A., Fuster-Casanovas A., Börve A., Yélamos O., Fustà-Novell X., Rafat M.E., Marin-Gomez F.X., Vidal-Alaball J.. Using Artificial Intelligence as a Diagnostic Decision Support Tool in Skin Disease: Protocol for an Observational Prospective Cohort Study. Jmir Research Protocols. 2022; 11(8)DOI:10.2196/37531. PMID:. IF:(Q/D).
01/01/2022
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey
Bechman K., Cook E.S., Dand N., Yiu Z.Z.N., Tsakok T., Meynell F., Coker B., Vincent A., Bachelez H., Barbosa I., Brown M.A., Capon F., Contreras C.R., De La Cruz C., Meglio P.D., Gisondi P., Jullien D., Kelly J., Lambert J., Lancelot C., Langan S.M., Mason K.J., McAteer H., Moorhead L., Naldi L., Norton S., Puig L., Spuls P.I., Torres T., Urmston D., Vesty A., Warren R.B., Waweru H., Weinman J., Griffiths C.E.M., Barker J.N., Smith C.H., Galloway J.B., Mahil S.K.. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2)DOI:10.1111/bjd.21042. PMID:35104366. IF:10.300(Q1/1D).
01/01/2022
Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies
Zachariae C., Mrowietz U., Strodl Andersen J., Puig L.. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4)DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2.500(Q2/5D).